Ottawa needs to reset its relationship with drug developers
Politicians have to stop creating impediments to access
Read More
Author: Nigel Rawson
Gene therapy appraisals may limit new drugs in Canada
Canada’s separate environmental protection oversight unnecessarily delays development and approval
Read More
Denying hope and health to Canadians with rare disorders
Manufacturers must overcome several federal government hurdles before patients have access to drugs
Read More
Ottawa blocking Canadians’ access to innovative drugs
Health Canada’s revisions to the drug-pricing review board will delay or prevent access to new drugs
Read More
Proposed changes could reduce access to prescription drugs
While well-intentioned, changes to Patented Medicine Prices Review Board could stop companies from launching new drugs
Read More